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Background: Children are particularly susceptible to tuberculosis. However, most children exposed to Myco-
bacterium tuberculosis are able to control the pathogen without evidence of infection. Correlates of human
protective immunity against tuberculosis infection are lacking, and their identification would aid vaccine
design.
Methods: We recruited pairs of asymptomatic children with discordant tuberculin skin test status but the
same sleeping proximity to the same adult with sputum smear-positive tuberculosis in a matched case-con-
trol study in The Gambia. Participants were classified as either Highly TB-Exposed Uninfected or Highly TB-
Exposed Infected children. Serial luminescence measurements using an in vitro functional auto-luminescent
Bacillus CalmetteGuerin (BCG) whole blood assay quantified the dynamics of host control of mycobacterial
growth. Assay supernatants were analysed with a multiplex cytokine assay to measure associated inflamma-
tory responses.
Findings: 29 pairs of matched Highly TB-Exposed Uninfected and Highly TB-Exposed Infected children aged 5
to 15 years old were enroled. Samples from Highly TB-Exposed Uninfected children had higher levels of
mycobacterial luminescence at 96 hours than Highly TB-Exposed Infected children. Highly TB-Exposed Unin-
fected children also produced less BCG-specific interferon-g than Highly TB-Exposed Infected children at
24 hours and at 96 hours.
Interpretation: Highly TB-Exposed Uninfected children showed less control of mycobacterial growth com-
pared to Highly TB-Exposed Infected children in a functional assay, whilst cytokine responses mirrored infec-
tion status.
Funding: Clinical Research Training Fellowship funded under UK Medical Research Council/Department for
International Development Concordat agreement and part of EDCTP2 programme supported by European
Union (MR/K023446/1). Also MRC Program Grants (MR/K007602/1, MR/K011944/1, MC_UP_A900/1122).
© 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license.
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l., Protection against mycobacterial infection: A case-control study of mycobacterial immune
discordant infection status despite matched TB exposure, EBioMedicine (2020), https://doi.org/1. Introduction
The WHO have set the ambitious goal of ending TB by 2035 and
achieving zero childhood TB deaths [1,2]. Key to this is the develop-
ment of effective vaccines, which requires identification of correlates
Research in context
Evidence before this study
Over one million children develop tuberculosis each year, often
through household exposure to an adult with pulmonary tuber-
culosis. However, most children with such exposure develop
neither tuberculosis disease, nor latent tuberculosis infection
(LTBI) and these individuals are important to study to under-
stand protective immunity.
Studies using functional whole blood mycobacterial growth
assays have shown superior growth control by adults with LTBI
compared to healthy controls, whilst another study including
children found no difference. Production of the cytokine inter-
feron-g (IFNg) is the basis of blood tests for LTBI, whilst
Tumour-Necrosis Factor-a (TNFa) production has also been
linked to responses in the tuberculin skin test for LTBI. How-
ever, differences in TNFa responses to mycobacterial stimula-
tion have not been consistently found in household TB contact
studies.
Search strategy: PubMed was searched using the terms
“immun* AND ("latent tuberculosis" OR "tuberculosis infec-
tion")” with a filter of “Child: birth-18 years” and no date or
language limitations on 10/6/20.
Added value of this study
To our knowledge, this is the first study of children with high
exposure to TB but who have not developed disease or LTBI
that has used an exposure-matched case-control design. We
recruited pairs of asymptomatic children with discordant
tuberculosis infection status but the same sleeping proximity
to the same adult with sputum smear-positive tuberculosis
in The Gambia. Using a whole blood autoluminescent myco-
bacterial growth assay we found that High TB-Exposure
Uninfected children had less control of mycobacterial growth
at 96 h than matched High TB-Exposure Infected children.
Multiplex cytokine analysis of supernatants from this assay
showed interferon-g responses reflected LTBI status but
no significant differences in TNFa and other measured
cytokines.
Implications of all the available evidence
Children with effective immunity against tuberculosis infection
are an important study population to try to identify correlates
of protection that can guide vaccine design and evaluation. In
vitro experiments using clinical samples that focus on gene
expression, inflammatory and innate immune responses, and
antibody effector function may be helpful in future studies.
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important and interesting population, as although young children are
susceptible to disease progression and have high morbidity and mor-
tality, early school-age children appear to be relatively protected
against development of tuberculosis, and some children show no
signs of disease or asymptomatic infection despite defined exposure
to infectious cases of pulmonary tuberculosis [5,6]. Latent tuberculo-
sis infection (LTBI) is a clinically relevant phenotype because the risk
of incident tuberculosis is significantly higher in children of all ages
with a positive baseline tuberculin skin test (TST) or Interferon
Gamma Release Assay (IGRA) compared to those with negative base-
line tests [7,8]. Building on paediatric observational data, there is
now clinical trial evidence that Bacillus CalmetteGuerin (BCG) vac-
cine protects against TB infection [911]. This highlights that it is a)
Please cite this article as: R. Basu Roy et al., Protection against mycob
responses in pairs of Gambian children with discordant infection status
10.1016/j.ebiom.2020.102891possible to induce a protective immune response and b) the impor-
tance of studying those who have neither tuberculosis disease nor
infection despite exposure toM tuberculosis (MTB).
Nevertheless, the biological basis of both natural and vaccine-
inducible human protection against TB infection remains poorly
understood [12]. Genetic loci associated with TST responses overlap
with a region associated with Tumour Necrosis Factor-a (TNFa) pro-
duction [1317]. Enhanced antibody avidity and distinct MTB-spe-
cific IgG Fc profiles as well as a role for NK cells, and changes in
innate immune cell subpopulations over time have all been impli-
cated [1823]. Identification of such correlates of protective human
immunity against infection are critical to design and evaluation of
novel vaccines for prevention of infection and to shorten the duration
of costly clinical trials [24].
One potential correlate of protection is mycobacterial growth
inhibition by either whole blood or peripheral blood mononuclear
cells [2528]. The BCG-lux assay, a functional mycobacterial growth
inhibition assay, employs reporter-gene tagged mycobacteria [29,30].
In this assay, a growth ratio is calculated based on luminescence of
recombinant mycobacteria following lysis of in vitro infected whole
blood samples at baseline and 96 hours. An alternative Mycobacterial
Growth Inhibition Assay (MGIA) uses readouts of time to positivity in
automated BD BacTec culture systems following inoculation of a
blood sample with mycobacteria [25,26]. Both the BCG-lux assay and
the BacTec-based MGIA provide a single numerical value as the result
and do not capture the dynamics of early host-mycobacterial
interactions.
Household studies of contacts of a TB index case are a useful epi-
demiological platform through which to investigate the spectrum of
immune responses to MTB exposure [31]. Such studies generally
compare groups of participants with a particular phenotype from the
study population. Interpretation of results is complicated by variation
in infectiousness of the source case, duration and intensity of the
interaction, infectivity of the organism, and the child’s immune status
[5,3235]. We therefore instead conducted a matched case-control
study nested within an established household contact platform in
The Gambia [31,34,3638]. We recruited pairs of asymptomatic chil-
dren with discordant TST despite the same sleeping proximity to the
same smear-positive adult with recently diagnosed pulmonary tuber-
culosis. This study design therefore minimises confounding as within
each pair the children will have been exposed to the same strain of
MTB from the same adult with the same index case characteristics.
We recruited participants older than five years old, to focus on the
age range where children are relatively protected against TB disease.
This also prevented confounding through isoniazid preventive ther-
apy provision for all household contacts under five in keeping with
WHO recommendations [5,6,38].
We also developed a novel autoluminescent recombinant BCG
whole blood mycobacterial growth inhibition assay with serial, non-
destructive measurement of luminescence on the same sample,
thereby enabling study of the dynamics of the host-mycobacterial
interaction using minimal blood volumes [39]. This method also ena-
bles biochemical analysis of supernatants from the BCG-infected
whole blood samples to evaluate the profile of pro- and anti-inflam-
matory cytokine responses implicated in host control of mycobacte-
ria such as interferon g (IFN-g), TNFa, Interleukin-1a and b (IL-1a,
and IL-1b), and IL-10 [40]. We hypothesized that Highly TB-Exposed
Uninfected children would be better able to restrict mycobacterial
growth at early time points in the in vitro assay than their matched
Highly TB-Exposed Infected counterparts. We also hypothesised that
Highly TB-Exposed Uninfected children would have a pro-inflamma-
tory profile at early timepoints in the assay (with high levels of TNFa,
IL-1a, and IL-1b, and low levels of IL-10) associated with an effective
innate immune response, whilst the adaptive response of Highly TB-
Exposed Infected children would lead to elevated levels of IFN-g at
later timepoints.acterial infection: A case-control study of mycobacterial immune
despite matched TB exposure, EBioMedicine (2020), https://doi.org/
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Recruitment: All household compounds that were originally
enroled in the childhood TB household contact platform at MRC Unit
The Gambia between 1st January 2015 and 31st December 2015
were evaluated for inclusion in this study [34,3638]. Briefly, adult
index cases (>15 years old) with newly identified smear-positive pul-
monary tuberculosis were approached for consent to visit their
household compounds. A compound was defined as a cluster of
homes or buildings often owned by members of the same family,
with typically 78 child contacts per index case [34]. Families within
this compound were then consented for their children <15 years old
to be screened for symptoms of tuberculosis and a TST. Those with a
TST 10 mm or symptoms were referred to clinic for evaluation. All
participants were screened for symptoms of tuberculosis 3-monthly
for one year. Neonatal BCG immunisation coverage in The Gambia is
estimated at 98% [41].
Sample size calculation: This was based upon unpublished pilot
data from children with tuberculosis exposure using the BCG-lux
assay (Supplementary Fig. 1). Assuming a paired test to allow for
matching, data were bootstrapped with age matching. Taking 10,000
bootstrapped samples of size 30 in each group gave a power of 80%
for demonstrating a significant difference for a two-sided non-
parametric Wilcoxon signed-rank test at the 5% level.
Case definitions: Case definitions and inclusion and exclusion crite-
ria that were used to identify Highly TB-Exposed Infected and Highly
TB-Exposed Uninfected children for this study are summarised in
Supplementary Tables 1 and 2 [34]. Matched pairs of children had
the same sleeping proximity in the same building to the same adult
with smear-positive pulmonary tuberculosis. Children aged less than
5 years old were excluded as they were prescribed isoniazid preven-
tive therapy in line with WHO recommendations [38]. Participants in
this study were not treated for LTBI in keeping with WHO guidelines
at the time in view of their age and the absence of HIV infection [42].
All participants were asymptomatic at the time of initial household
symptom screening and were recruited to this study at least 3
months after the initial screening for a repeat TST to confirm that the
children identified as Highly TB-Exposed Uninfected had clear evi-
dence of having remained uninfected (TST 5 mm). Highly TB-
Exposed Infected children had an initial TST 10 mm in keeping with
WHO thresholds for a positive TST, a negative HIV test, a normal chest
radiograph, and a normal physical examination by a paediatrician
[42]. An in-house IGRA was taken from Highly TB-Exposed Infected
children at this initial clinic visit. Where more than one child in the
compound met the criteria for being Highly TB-Exposed Uninfected
or Highly TB-Exposed Infected, a single child from those eligible was
selected at random. Demographic and exposure data were collected
by the study fieldworker. The consent process included permission to
access the HIV status of the tuberculosis index case that had been
tested as part of routine clinical care in this low HIV prevalence set-
ting [34].
Sample procedures: Venous blood from matched Highly TB-
Exposed Uninfected and Highly TB-Exposed Infected children was
collected at the same visit. Samples were collected using lithium hep-
arin tubes for the whole blood assay and EDTA tubes for full blood
count (both BD, Oxford, UK). Full blood counts were analysed by the
Clinical Services Diagnostic Haematology Laboratory at MRC Unit The
Gambia at LSHTM using the Cell Dyn 3700 Haematology Analyser
(Abbott Diagnostics, Illinois). If this was not available, full blood count
samples were run using Medonics M-series (Boule Medical AB,
Spanga, Sweden) in the Immunology Research Laboratory. Samples
from both members of a pair were always analysed with the same
method. Monocyte: lymphocyte ratios were also calculated [43]. In-
house interferon gamma release assays on Highly TB-Exposed
Infected children were conducted as has previously been described
[36,44,45].Please cite this article as: R. Basu Roy et al., Protection against mycob
responses in pairs of Gambian children with discordant infection status
10.1016/j.ebiom.2020.102891Autoluminescent BCG growth monitoring in whole blood: The
method has been fully reported [39]. In brief, BCG Danish was trans-
formed to express the Luciferase Full Operon of Photorhabdus lumi-
nescens (RRID:Addgene_49999 with RRID: Addgene_50000) and
green fluorescent protein (RRID:Addgene_30173) with a ratio of 0.05
Relative Light Units(RLU)/ml/s: 1 Colony Forming Unit (CFU). Aliquots
were grown to logarithmic growth phase in liquid culture with anti-
biotic selection markers (kanamycin 20 mg/ml [Glyco/Life Technolo-
gies, Carlsbad, CA, USA] and hygromycin 50 mg/ml [Sigma-Aldrich,
Gillingham, UK]) and diluted to 3.3 £ 105 RLU/ml/s immediately prior
to venepuncture. Samples from both members of a pair were always
analysed in the same experiment. Heparinised whole blood was
diluted 1:1 with RPMI 1640 culture medium (Sigma-Aldrich, Gilling-
ham, UK) containing 2.5% 1 M HEPES buffer and 1% L-glutamine (both
Sigma-Aldrich). BCG-GFP-LuxFO was added at a ratio of 1 part BCG-
GFP-LuxFO: 9 parts whole blood in culture medium (equivalent to
1.3 £ 105 CFU per 100 mL undiluted whole blood). For the control
samples, bacterial medium alone was added in the same ratio of 1:9.
500ml was aliquoted in triplicates for each experimental condition at
each timepoint into sterile lidded 75 £ 12 mm polystyrene tubes
(Corning B.V Life Sciences, Amsterdam, The Netherlands) and trans-
ferred to a rocking incubator at 37 °C. Luminescence readings of each
tube were measured immediately after removal from the incubator
using a Sirius Tube Luminometer (Berthold Detection Systems GmbH,
Pforzheim, Germany) 1, 4, 24, 48, 72 and 96 hours after the bacteria
were added, and corrected for background luminescence. The base-
line luminescence reading was taken one hour after inoculation of
samples to ensure equilibration to a temperature of 37 °C in the incu-
bator [39]. In addition, at baseline (0 h), 24 hours, and 96 hours, fur-
ther sets of triplicate samples were centrifuged at 2000 x g for ten
minutes and supernatants stored at 70 °C and shipped on dry ice to
Imperial College London for cytokine analysis. Experimenters were
not blinded to group assignment for the experimental work.
Cytokine analysis: Triplicate supernatant aliquots were thawed,
pooled, and sterile filtered by spinning for 10 min at 5000 RPM with
0.22 mm centrifuge Spin-X tube filters (Corning B.V Life Sciences,
Amsterdam, The Netherlands), transferred to 96 well plates and
stored at 70 °C prior to analysis. A standardised custom commercial
multiplex magnetic bead-based immunoassay, Bio-Plex Pro (Bio-Rad,
Hercules, CA, USA), was used to quantify levels of IL-1a and IL-1b, IL-
10, IFN-g , TNF-a following the manufacturer’s instructions. All sam-
ples from matched Highly TB-Exposed Infected / Highly TB-Exposed
Uninfected pairs were run on the same plate and read using a Lumi-
nex 200 plate reader (LuminexCorp, Austin, Tx, USA). Quality control
samples made up of pooled supernatants from non-study assays
were run in duplicate on each plate and a normalisation factor
applied to ensure comparability between plates. Samples falling
below the quantification level of the assay were allocated values 1=4
of the lower limit of detection.
Statistical analysis: We used normal quantile plots and Shapiro-
Wilk tests to assess data distribution. To conduct unadjusted bivari-
ate tests for association, the matched paired t-test was used for nor-
mally distributed data, Wilcoxon’s matched pairs signed rank test for
non-normally distributed data, and McNemar’s x2 test for binary var-
iables. To examine multivariable associations of luminescence data
multi-level linear regression (or mixed effects linear modelling) was
used [46]. Luminescence data was log transformed due to the skew-
ness of the data. The matched pairs and the individual participants
were considered as random effects, whilst Highly TB-Exposed Unin-
fected / Highly TB-Exposed Infected status, age (as a categorical vari-
able in tertiles), being a sibling of the adult index case and
experimental time point were considered as fixed effects, the combi-
nation of all of which were used to predict log luminescence (depen-
dant variable). Estimated marginal means and 95% confidence
intervals for luminescence by group and time were predicted from
the model treating all fixed effects including age and whether theacterial infection: A case-control study of mycobacterial immune
despite matched TB exposure, EBioMedicine (2020), https://doi.org/
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interpretation of differences between groups at each time point was
carried out through pairwise comparisons [46]. STATA Statistical
Software: Release 12.1. (StataCorp LP, College Station, TX) and Prism
7 for MacOS X (Graphpad Software Inc) were used.
Ethical approvals: The study was approved by The Gambia Govern-
ment/MRC Joint Ethics Committee (SCC1405 and SCC1273) and the
Imperial College Healthcare Tissue Bank (R13071).
3. Results
3.1. Participant characteristics
A total of 58 children were recruited to the study from 29 different
residential compounds. The study recruitment profile is shown in
Fig. 1. Demographic features of the study participants together with
descriptive statistics are detailed in Table 1. Highly TB-Exposed
Infected children were significantly older than Highly TB-Exposed
Uninfected children (Highly TB-Exposed Infected: 10.37, interquartile
range (IQR) 9.4312.36; Highly TB-Exposed Uninfected:7.89, IQR:
7.0110.86, p = 0.027). 54 (93%) of the children were sleeping in the
same house as the adult index case, and 4 (7%) were sleeping in the
same room as the adult index case. The proportion of study partici-
pants where the adult index case was their parent did not signifi-
cantly differ between groups (Highly TB-Exposed Infected children:
7/29, Highly TB-Exposed Uninfected children: 4/29; p = 0.45). Highly
TB-Exposed Infected children were significantly more likely to be a
sibling of the adult (>15 years old) index case (10/29) than Highly
TB-Exposed Uninfected children (3/29, p = 0.02). Highly TB-Exposed
Infected children had a median TST of 18 mm with a range of 13 mm
to 25 mm (interquartile range 16 to 20 mm). All 29 Highly TB-
Exposed Uninfected children had a TST of 0 mm both at baseline and
between 3 and 12 months later. None of the Highly TB-Exposed
Infected children who were seen in clinic had HIV infection and 28/Fig. 1. Study recruitment profile.
TST = Tuberculin Skin Test, IGRA = Interferon Gamma Release Assay.
Please cite this article as: R. Basu Roy et al., Protection against mycob
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who did not consent for HIV testing was not a parent of the Highly
TB-Exposed Infected or Highly TB-Exposed Uninfected children. 25 of
the 29 Highly TB-Exposed Infected children had a positive in-house
IGRA at the initial clinic visit concordant with their positive TST
result. 3 Highly TB-Exposed Infected children had a negative IGRA
and 1 had an indeterminate IGRA at their initial clinic visit (Fig. 1).
There were no significant differences in haematological parameters,
including monocyte: lymphocyte ratio, between Highly TB-Exposed
Infected and Highly TB-Exposed Uninfected groups (Table 1). No par-
ticipant developed tuberculosis during 12 months of follow-up.
In vitro control of BCG bacterial growth: Bacterial growth in whole
blood was measured by luminescence at 6 timepoints, resulting in
longitudinal bacterial growth profiles in blood from all 58 partici-
pants. Infected blood from Highly TB-Exposed Infected children had
8.5% lower luminescence at baseline (median 402.4, IQR: 327.6 -
416.7 RLU/s) compared to Highly TB-Exposed Uninfected children
(median 439.7, IQR: 356.4 - 554 RLU/s; p = 0.0069). This difference
was not statistically significant at intermediate timepoints, but at
96 hours, there was 38% lower bacterial luminescence in samples
from Highly TB-Exposed Infected (median 11,511, IQR: 821015,272
RLU/s) compared to Highly TB-Exposed Uninfected children (median
15,895, IQR 965519,585 RLU/s; p = 0.0455) (Fig. 2, Supplementary
Fig. 2). Mixed effects modelling, treating age, whether the child was a
sibling of the index case, and other variables as balanced between
groups, modelled Highly TB-Exposed Infected children to have lower
luminescence than Highly TB-Exposed Uninfected children at base-
line, although this was not statistically significant (Highly TB-Exposed
Infected: Modelled estimated marginal mean (MEMM): 400.8, 95% CI:
332.7482.8 RLU/s; Highly TB-Exposed Uninfected: MEMM: 456.6,
95%CI 374.8556.2 RLU/s; p value=0.09, Table 2 and Supplementary
Table 3). Highly TB-Exposed Infected children had significantly lower
modelled luminescence than Highly TB-Exposed Uninfected children
at 96 hours (Highly TB-Exposed Infected: MEMM: 11,262 RLU/s, 95%acterial infection: A case-control study of mycobacterial immune
despite matched TB exposure, EBioMedicine (2020), https://doi.org/
Table 1
Summary of participant characteristics.
Characteristic Highly TB-exposed uninfected children Highly TB-exposed infected children p
n 29 29 
Sleeping proximity Same room 2 2 
Same house 27 27 
Different house 0 0 
Median age in years (IQR) 7.89 (7.0110.86) 10.37 (9.4312.36) 0.027a
% Males 14 (48) 16 (55) 0.62b
HIV infection in child (n = 29)  0 
HIV infection in adult index case (adult consented to test n = 28) 0
Relationship of child to adult index case (%) Child 4 (13.8) 7 (24.1) 0.45b
Cousin 6 (20.7) 2 (6.9) 0.13b
Grandchild 1 (3.4) 2 (6.9) 1.00b
Nephew or Niece 9 (31.0) 6 (20.7) 0.45b
Sibling 3 (10.3) 10 (34.5) 0.02b
Distant relation 1 (3.4) 1 (3.4) 1.00b
Unrelated 5 (17.2) 1 (3.4) 0.13b
Median initial TST result in mm (IQR) 0 (0) 18 (1620) 0.000a
Median repeat TST result in mm (IQR) 0 (0)  
Initial Interferon Gamma Release Assay Positive  25 (86.2%) 
Negative  3 (10.3%) 
Indeterminate  1 (0.3%) 
Median absolute White blood cell count k/mL (IQR) 6.38 (5.587.18) 6.02 (5.66.75) 0.563a
Mean absolute monocyte count k/mL (95% CI) 0.467 (0.3810.552) 0.443 (0.3520.534) 0.657c
Median absolute neutrophil count k/mL (IQR) 2.44 (1.882.83) 2.61 (2.173.19) 0.492a
Mean absolute lymphocyte count k/mL (95% CI) 2.90 (0.994.80) 2.67 (0.914.44) 0.391c
Mean Monocyte:Lymphocyte ratio (95% CI) 0.174 (0.1410.206) 0.171 (0.1380.204) 0.905a
a denotes Wilcoxon matched pairs signed rank test.
b McNemar’s x2 test.
c denotes paired t-test. Haematological statistics based upon results available from CellDyn machine (Highly TB-Exposed Infected n=25, Highly TB-Exposed
Uninfected n=25).
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13,304 RLU/s, 95% CI: 10,92116,206, p = 0.031). Similar patterns
were seen in the sub-analysis where the Highly TB-Exposed Infected
children with negative or indeterminate baseline IGRAs where
excluded (Supplementary Fig. 3).
Cytokine responses to BCG bacteria in Highly TB-Exposed Uninfected
versus Highly TB-Exposed Infected children: Data were available for all
58 children for baseline and 96-hour timepoints. There was insuffi-
cient sample from one Highly TB-Exposed Uninfected child for the
24-h timepoint, and therefore data from 28 pairs was analysed for
this timepoint. After the baseline timepoint, all cytokine levels were
quantifiable in response to in vitro infection with BCG, except for IFN-
g in one 24-hour timepoint sample. BCG-specific IFN-g responses
were higher in blood from Highly TB-Exposed Infected children at
24 h (median 50.44 pg/ml, IQR 23.1575.36) than Highly TB-Exposed
Uninfected children (median 30.06pg/ml, IQR 14.6450.86,
p = 0.0232, Fig. 3a, Table 3, Supplementary Fig. 4). Highly TB-Exposed
Infected children also had higher levels of BCG-specific IFN-g at 96 h
(median 197.2 pg/ml, IQR 125.4418.3) compared to Highly TB-
Exposed Uninfected children (median 121.4pg/ml, IQR 59.53231;
p = 0.0138). The BCG-specific IFN-g responses were similar between
the 25 Highly TB-Exposed Infected children with a concordant posi-
tive IGRA and those 4 Highly TB-Exposed Infected children with dis-
cordant negative or indeterminate IGRA (Supplementary Fig. 5).
TNFa responses were not significantly different in Highly TB-Exposed
Infected children at 24 h (median 2605 pg/ml, IQR 14353850) com-
pared to Highly TB-Exposed Infected children (median 2053 pg/ml,
IQR 16352746, p = 0.2545, Fig. 3b, Table 3)). At 96 h, TNFa responses
were higher in Highly TB-Exposed Infected children (median
667.6pg/ml, IQR 421.4959.2) than Highly TB-Exposed Uninfected
children (median: 386pg/ml, IQR 268.8622.3) although this was not
statistically significant (p = 0.096) There were no statistically signifi-
cant differences between IL1a, IL1b, and IL10 responses to BCG in
whole blood from Highly TB-Exposed Uninfected and Highly TB-
Exposed Infected children (Fig. 3ce, Table 3).
Please cite this article as: R. Basu Roy et al., Protection against mycob
responses in pairs of Gambian children with discordant infection status
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Given the importance of understanding human protective immu-
nity to LTBI to guide vaccine design and evaluation, we applied a
novel functional mycobacterial assay in a tuberculosis-endemic coun-
try to children with a persistently negative TST despite defined
household MTB exposure. We conducted a carefully matched study
of children with discordant infection status despite the same sleeping
proximity to the same adult with smear-positive pulmonary tubercu-
losis. We utilised a whole blood autoluminescent BCG growth assay
to identify differences in functional control of mycobacteria and cyto-
kine responses in these individuals that could correlate with protec-
tion against infection. The potential to identify functional differences
in the dynamics of host-mycobacterial interactions using small vol-
umes of blood is a major advantage of the autoluminescent proper-
ties harnessed in this method, and is not possible with other whole
blood mycobacterial assays. [25,26,29,39,47,48]
We hypothesised that Highly TB-Exposed Uninfected children
would exhibit superior mycobacterial control as measured by lower
experimental luminescence at early experimental timepoints than
Highly TB-Exposed Infected children. Non-parametric bivariate tests
of luminescence one hour after infection instead showed a statisti-
cally significant opposite effect. The observation was not significant
in mixed effects modelling incorporating the longitudinal nature of
the data, age, and inter-individual variability, so further investigation
is needed. The possible differences within only one hour after infec-
tion of samples suggest further research focusing on the trained
innate immune response may be of value [18,49,50]. A difference in
inoculum is unlikely to account for the differences in baseline and
96 h luminescence between the groups as all samples from a pair
were handled in the same way and inoculated with the same volume
from the same stock of BCG at the same time. Baseline luminescence
was measured one hour after inoculation to allow samples to equili-
brate to 37 °C in the incubator, and each triplicate tube was individu-
ally removed, measured, and returned, so there was a maximum ten-acterial infection: A case-control study of mycobacterial immune
despite matched TB exposure, EBioMedicine (2020), https://doi.org/
Fig. 2. Luminescence kinetics in the whole blood BCG assay for all Highly TB-Exposed Uninfected and Highly TB-Exposed Infected children. a) Graph and b) column scatterplots of
the data. Median values and interquartile ranges are shown. p values fromWilcoxon matched pairs signed rank test. Scale on y axis for each plot selected to optimise data display.
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6 R. Basu Roy et al. / EBioMedicine 00 (2020) 102891minute interval between measuring samples from the two children in
a pair [39]. We did not see differences in cytokine response at base-
line. Both non-parametric statistics and mixed effects modelling
showed significantly greater mycobacterial control by Highly TB-
Exposed Infected children at 96 h, mirroring results from two adult
studies, which used different functional mycobacterial growth assays
and suggest that MGIA are likely measuring adaptive responses at
this time-point [25,29,51]. However, a comparison of unmatched
groups of 20 IGRA-positive and 28 IGRA-negative 8 year-old South
African children did not demonstrate a difference in mycobacterialTable 2
Modelled estimated marginal means for luminescence of Highly TB
children Estimated marginal means and 95% confidence intervals by
effects including age as balanced. P values derived from pairwise com
Modelled estimated marginal means fo
Experimental timepoint Highly TB-exposed Infected (95% CI)
Baseline 400.78 (332.66482.84)
4 h 848.10 (703.951,021.76)
24 h 872.47 (724.181,051.12)
48 h 2,144.54 (1,780.052,583.66)
72 h 5,282.15 (4,384.386,363.76)
96 h 11,261.95 (9,347.8413,568.01)
Please cite this article as: R. Basu Roy et al., Protection against mycob
responses in pairs of Gambian children with discordant infection status
10.1016/j.ebiom.2020.102891growth inhibition [48]. Our luminescence data did not support supe-
rior mycobacterial control by Highly TB-Exposed Uninfected children
and we therefore rejected our hypothesis and found that lumines-
cence was not a correlate of protection in the assay’s current form.
The TST phenotype was dramatically different between the Highly
TB-Exposed Infected and Highly TB-Exposed Uninfected groups, with
Highly TB-Exposed Infected children strongly positive, and all Highly
TB-Exposed Uninfected children consistently having 0 mm results,
tested twice with a minimum of three months intervals. We found
that Highly TB-Exposed Infected children were older than Highly-Exposed Infected and Highly TB-Exposed Uninfected pairs of
group and time were predicted from the model treating all fixed
parisons of adjusted predictions.
r luminescence in relative light units/second (95%CI)
Highly TB-exposed Uninfected (95% CI) p
456.59 (374.81556.21) 0.092
889.31 (730.021,083.34) 0.54
970.13 (796.371,181.80) 0.171
2,307.49 (1,894.202,810.95) 0.345
6,005.02 (4,929.477,315.24) 0.098
13,303.89 (10,921.0616,206.62) 0.031
acterial infection: A case-control study of mycobacterial immune
despite matched TB exposure, EBioMedicine (2020), https://doi.org/
Fig. 3. BCG-specific cytokine levels for the 29 Highly TB-Exposed Infected and 29 Highly TB-Exposed Uninfected children.
a) IFNg , b) TNFa, b) IL1a, d) IL1b, and e) IL10. Median and interquartile ranges. P values from Wilcoxon matched pairs signed rank test. Scale on y axis for each plot selected to
optimise data display.
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8 R. Basu Roy et al. / EBioMedicine 00 (2020) 102891TB-Exposed Uninfected children, in keeping with data from preva-
lence studies, although the absolute difference in median age of
2.5 years in a study where all participants are older than five is
unlikely to explain such dramatic differences in TST results [5,33,52].
Highly TB-Exposed Infected children were also significantly more
likely to be a sibling of the adult index case, which may have implica-
tions for the nature of interactions with, and hence exposure to, the
index case. Both age and sibling status were included as variables in
the mixed effects modelling of luminescence data.
To our knowledge, our study is the first to apply a matched study
design to the evaluation of whole blood cytokine responses to myco-
bacteria in children without LTBI despite exposure. Highly TB-
Exposed Infected children produced significantly more IFN-g in
response to BCG at 24 and 96 hours. IFN-g is recognised as a neces-
sary but not sufficient mediator of host response to mycobacteria and
is of course the basis of IGRAs [5]. In keeping with our findings, in
two distinct cohorts in Uganda and Pakistan, IFN-g levels in response
to mycobacterial stimulation were also found to be lower in persis-
tently TST negative individuals compared to those with LTBI or those
who convert to a positive TST [5355].
We did not find statistically significant differences in TNF-a levels
as has also been previously observed [53,54,56]. The absence of sig-
nificantly different cytokine results between groups are also in con-
cordance with other published studies. Although there was not a
matched design and the number of paediatric participants is not
clear, persistently IGRA negative Indonesian household TB contacts
in comparison to those who converted to a positive IGRA showed no
difference in levels of TNF-a, IL1b, IL-1RA, IL-10, IL-6 and IL-8 in
response to in vitro BCG infection or stimulation with an MTB lysate
[18]. There was also no difference in IL-2, IFN-g , TNF-a, and/or IL-
17-expressing subsets of CD4, CD8 and gd T-cells between IGRA+ and
IGRA- South African adults following 12 h of BCG stimulation, nor
correlations with MTB growth in a cross-sectional study [48]. Cyto-
kine responses to MTB antigens of samples from babies born to moth-
ers with or without LTBI also do not differ [57].
Our study had notable strengths in its matched design, clear dif-
ferences in the TST phenotype, and confirmation of persistent TST
negativity for at least 3 months in the Highly TB-Exposed Uninfected
children. The application of the novel autoluminescent BCG whole
blood assay enabled the possibility to examine the kinetics of host-
mycobacterial interactions in children using minimal blood volumes.
However, our study also had limitations. The sample size was not
large, although the number of children was greater or comparable to
other studies in the field [18,48]. Due to the limited sample capacity
of laboratory equipment and the importance of simultaneous con-
duct of the functional mycobacterial assay on samples from matched
children in the same experiment, it was not possible to recruit every
Highly TB-Exposed Infected and Uninfected child. The study was con-
ducted in a single centre. IGRA status was only available at baseline
for the Highly TB-Exposed Infected children and was not available for
the Highly TB-Exposed Uninfected children. Nevertheless, excluding
the four IGRA/TST discordant Highly TB-Exposed Infected children
did not affect the results. Also, all of the Highly TB-Exposed Unin-
fected children maintained their TST results of 0 mm at baseline and
at least 3 months later and the likelihood of a positive IGRA would be
low. The Highly TB-Exposed Infected children were classified as such
following initial screening; therefore, we cannot be certain whether
their infection status was secondary to the identified recent house-
hold exposure or more longstanding. Data on additional epidemio-
logical factors such as ventilation, use of mosquito nets, school
attendance and movement within and outside the household are not
available. With regard to the immune status of the children, no HIV
infection was identified in the Highly TB-Exposed Infected children
or the adult index cases who were tested. Although the study design
meant that within matched pairs of children exposure was to the
same index case (and hence strain of MTB), mycobacterial culture onacterial infection: A case-control study of mycobacterial immune
despite matched TB exposure, EBioMedicine (2020), https://doi.org/
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R. Basu Roy et al. / EBioMedicine 00 (2020) 102891 9adults with pulmonary tuberculosis was not routine within the Gam-
bian National Leprosy and Tuberculosis Control Program so data on
MTB lineage and strains in the index cases are not available. Our
study used BCG as the mycobacterial stimulus rather than pathogenic
MTB. However, inoculum strain has been shown not to be a major
determinant in mycobacterial growth inhibition assays in a high TB-
prevalence setting, where BCG, MTB H37Rv, a W/Beijing MTB strain
HN878, and Euro-American MTB strain, CDC1551 were all used to
compare individuals with and without LTBI, including children and
young adults [48]. The experimental stimulus being BCG in a popula-
tion with near universal coverage of neonatal BCG vaccine, may have
contributed to the similarity of cytokine responses between groups,
except for IFN-g levels that matched infection status. Nevertheless,
the significant difference in luminescence at 96 h between groups
suggests that even against this background of BCG vaccination and
environmental mycobacterial exposure, the assay is able to distin-
guish children by their LTBI status. It may be that we were not able to
detect differences in luminescence at early timepoints due to the
need for a relatively high multiplicity of infection, as a consequence
of the relatively low autoluminescence of the bacteria, in order for
baseline measurements to be within the dynamic range of the lumin-
ometer [39].
We have demonstrated the importance of careful exposure-
matched study design when comparing experimental data on sam-
ples from patients with LTBI to those who remain uninfected despite
TB contact. We would encourage such study designs to be adopted
more widely. We have also employed for the first time an autolumi-
nescent mycobacterial growth assay specifically designed for paedi-
atric studies where serial non-destructive luminescence
measurements and supernatant analysis were possible with less than
5mls total blood. In conclusion, we found no evidence for a superior
ability to restrict mycobacterial growth in vitro in children who were
MTB exposed but remained uninfected, compared to their well-
matched counterparts. We also did not identify any key pro-inflam-
matory cytokine responses to BCG associated with remaining unin-
fected. Identifying correlates of protection against LTBI remains
challenging. We suggest a continued research focus on persistently
TST negative individuals despite exposure, with application of novel
and improved functional assays, broader investigation of trained
innate immunity, antibody effector function, gene expression and
genetic diversity, and metabolomic differences needed to yield fur-
ther biological insights that can be applied to guide vaccine design
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